Αρχική World News FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer World News FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer Από Ogkologos - 4 Ιουλίου, 2025 898 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Woman Suffers Severe Eye Pain And Swelling, Finds Out She Has... 17 Απριλίου, 2019 FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib... 30 Μαΐου, 2025 Cooperativity of BRAF/MAPK Pathway Inhibition and Immune Checkpoint Blockade in Patients... 3 Φεβρουαρίου, 2023 Ahead of a Key Meeting of EU Health Ministers, ESMO Calls... 14 Ιουνίου, 2026 Φόρτωση περισσοτέρων HOT NEWS Women in science: Cancer research pioneers – part 2 Adjuvant Dabrafenib Plus Trametinib Associated with Better RFS and DMFS than... What to Know About Navigating Cancer Care With a Disability: An... Apalutamide Plus ADT Demonstrates a Rapid, Deep, and Durable PSA Decline...